Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a new drug tame ewing sarcoma when others fail?

NCT ID NCT07781891

Disease control Sponsor: M.D. Anderson Cancer Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 24, 2026 · Last updated Aug 25, 2026 · Updated 1 time

Summary

This phase 2 trial is testing an experimental drug called LX-101 to see if it can help control Ewing sarcoma and related tumors (DSRCT and SRCS) that have come back or stopped responding to standard chemotherapy. The study enrolls adolescents and young adults (age 10 and up) who have already tried at least two prior chemotherapy regimens. Participants receive LX-101 by injection, and researchers monitor safety and how well the drug works.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
LX-101 (an experimental anticancer drug given by injection)
What this could lead to
If successful, this trial could identify new drug options that help control Ewing sarcoma and related tumors when standard treatments have failed.
What could go wrong
This is an early-phase trial, so the drug may not work or may cause unexpected side effects. Results are not yet known.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 120 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Feb 2027

An estimate. Start dates often move.

Expected to finish

Jun 2033

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

10 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Eligibility Criteria A. Age ≥ 10 years (Safety data from ≥3 adult patients must exist before enrolling children). B. Must have relapsed or chemo-refractory ES, DSRCT, or SRCS. C. Must have received at least 2 prior chemotherapy regimens (typically VIDE or VDC/IE) D. Measurable disease by RECIST (i.e., tumor ≥1 cm in minimal dimension) E. ECOG performance status is 0-2 for adults (Karnofsky/Lansky score ≥60 for children \<16 years of age) F. \>1 week washout period from any investigational agent and resolution of drug-related AE/SAE to ≤ grade 2. Exclusion Criteria: A. Uncontrolled or severe cardiac, neurologic, pulmonary, pancreatic, renal, or liver disease. B. No known personal family history of Long QT syndrome C. History of organ transplant (other than autologous stem cell transplant for cancer), active pneumonitis, myelodysplastic syndrome, or leukemia (acute or chronic) D. Immune or auto-immune-related disorders requiring treatment (treatment for eczema is allowed) E. Investigational agents within 7 days of starting study treatment. F. Major surgery within 28 days before treatment consent (Treatment cannot start with a persistent open wound) G. Leptomeningeal disease or untreated brain metastases. H. Unable to safely hold anticoagulant medication, if taken, for biopsy. I. Psychiatric illness/social situations that would limit compliance with study requirements. J. Prisoners or participants who are legally institutionalized.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Desmoplastic small round cell tumor are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

desmoplastic small round cell tumor Ewing sarcoma Recurrence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Ewing sarcoma

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • MD Anderson Cancer Center

    Houston, Texas, 77090, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.